23.2 Introduction to the Lower Respiratory System

Structure and Function of the Lower Respiratory System

The lower respiratory system moves air from the throat down into the lungs, where oxygen and carbon dioxide are exchanged. Understanding this anatomy is essential for nursing because most respiratory drugs target specific structures along this pathway.

Trachea, Bronchi, Bronchioles, Alveoli

The airway branches like an upside-down tree, getting smaller at each level. Each branch has different structural features that matter for how diseases develop and how medications reach their targets.

Trachea (the windpipe) connects the larynx to the bronchi. It's lined with ciliated pseudostratified columnar epithelium, which traps and sweeps debris upward. C-shaped cartilage rings keep it open; the open side faces the esophagus posteriorly.

Bronchi branch in a series of divisions:

• Primary bronchi form where the trachea splits (bifurcates) into left and right main airways. The right bronchus is shorter, wider, and more vertical, which is why aspirated objects tend to lodge there.
• Secondary (lobar) bronchi branch off to supply each lobe of the lung (3 on the right, 2 on the left).
• Tertiary (segmental) bronchi branch further to supply individual bronchopulmonary segments.

Bronchioles are smaller airways that branch from the tertiary bronchi. They lack cartilage, so their diameter depends on smooth muscle tone. This is why bronchodilators are so important: when that smooth muscle constricts, these airways narrow significantly.

• Terminal bronchioles are the smallest airways in the conducting zone (they move air but don't exchange gas).
• Respiratory bronchioles mark the start of the respiratory zone, where alveoli begin to appear and gas exchange occurs.

Alveoli are tiny, grape-like air sacs clustered at the ends of respiratory bronchioles. They're surrounded by dense capillary networks, creating a very thin barrier for gas exchange. Two cell types are clinically important:

• Type I alveolar cells are thin squamous cells that make up most of the alveolar surface. Their thinness allows efficient diffusion of $O_2$ and $CO_2$.
• Type II alveolar cells secrete surfactant, a substance that reduces surface tension and prevents the alveoli from collapsing during exhalation. Damage to these cells (or surfactant deficiency) leads to atelectasis.

Common Lower Respiratory Conditions

Asthma, COPD

These are the two most common chronic lower respiratory diseases you'll encounter. Both involve airflow limitation, but they differ in reversibility and underlying mechanism.

Asthma is a chronic inflammatory disorder characterized by airway hyperresponsiveness and reversible airflow obstruction. The airways overreact to triggers, causing bronchoconstriction, mucosal edema, and excess mucus production.

• Common triggers: allergens (pollen, dust mites), irritants (smoke, cold air), exercise, and respiratory infections
• Symptoms: wheezing, coughing (often worse at night), chest tightness, shortness of breath
• The reversibility is key: symptoms improve with bronchodilator use, which helps distinguish asthma from COPD

COPD is a group of progressive lung diseases characterized by persistent, largely irreversible airflow limitation. The two main forms often coexist:

• Chronic bronchitis involves inflammation and narrowing of the bronchi with increased mucus production. Patients are sometimes called "blue bloaters" because hypoxemia can cause cyanosis and fluid retention.
• Emphysema involves destruction of alveolar walls, creating enlarged air spaces that reduce the surface area for gas exchange. These patients are sometimes called "pink puffers" because they hyperventilate to compensate, maintaining near-normal oxygen levels but appearing breathless.

Smoking is the primary risk factor for COPD. Unlike asthma, the damage is progressive and not fully reversible, which is why prevention and early intervention matter so much.

Diagnostic Methods and Treatment Approaches

PFTs, Pharmacological Interventions

Diagnostic Methods

• Pulmonary Function Tests (PFTs) assess how well the lungs work:
  • Spirometry measures forced vital capacity ($FVC$) and forced expiratory volume in one second ($FEV_1$). The $FEV_1/FVC$ ratio is especially useful: a ratio below 0.70 suggests obstructive disease like COPD.
  • Peak Expiratory Flow Rate (PEFR) measures the maximum speed of expiration, commonly used for asthma monitoring at home.
  • Lung volume measurements assess total lung capacity ($TLC$) and residual volume ($RV$). Elevated $RV$ suggests air trapping, which is common in emphysema.
• Imaging studies (chest X-ray, CT scan) visualize lung structure and can reveal hyperinflation, consolidation, or masses.
• Arterial Blood Gas (ABG) analysis evaluates oxygenation ($PaO_2$) and ventilation ($PaCO_2$). This tells you whether a patient is adequately exchanging gases and helps identify respiratory acidosis or alkalosis.

Treatment Approaches

Pharmacological interventions target specific parts of the disease process:

• Bronchodilators relax airway smooth muscle to improve airflow:

  1. Short-acting beta-2 agonists (SABAs): albuterol, levalbuterol. These are "rescue" inhalers for acute symptoms, with onset in minutes.
  2. Long-acting beta-2 agonists (LABAs): salmeterol, formoterol. Used for maintenance therapy, not acute rescue. Always paired with an inhaled corticosteroid in asthma to avoid increased risk of severe exacerbations.
  3. Anticholinergics: ipratropium (short-acting), tiotropium (long-acting). Block parasympathetic bronchoconstriction. Particularly useful in COPD.

• Corticosteroids reduce airway inflammation:

  1. Inhaled corticosteroids (ICS): fluticasone, budesonide. Mainstay of asthma maintenance therapy. Remind patients to rinse their mouth after use to prevent oral thrush.
  2. Oral corticosteroids: prednisone, methylprednisolone. Reserved for acute exacerbations or severe disease due to systemic side effects with long-term use.

• Leukotriene modifiers (e.g., montelukast) block leukotriene-mediated inflammation and bronchoconstriction. Used as add-on therapy in asthma, especially for patients with exercise-induced or allergy-related symptoms.

Non-pharmacological approaches are equally important:

• Oxygen therapy provides supplemental $O_2$ for patients with hypoxemia. In COPD patients who are chronic $CO_2$ retainers, use low-flow oxygen (typically 1-2 L/min) to avoid suppressing their hypoxic respiratory drive.
• Pulmonary rehabilitation combines exercise training, breathing techniques, education, and psychosocial support. It's a cornerstone of COPD management.
• Smoking cessation is the single most effective intervention for slowing COPD progression. Nurses play a critical role in counseling and supporting patients through this process.